新光药业：和丰投资计划减持不超过3%公司股份

Group 1 - The core point of the announcement is that a major shareholder, Hongfeng Investment, plans to reduce its stake in XinGuang Pharmaceutical by up to 4.8 million shares, which represents a maximum of 3% of the company's total share capital [1] - The reduction will occur within three months starting from 15 trading days after the announcement, utilizing both centralized bidding and block trading methods [1] - Specifically, the shareholder intends to sell up to 1.6 million shares (1% of total share capital) through centralized bidding and up to 3.2 million shares (2% of total share capital) via block trading [1]